Home » Stocks » Diffusion Pharmaceuticals

Diffusion Pharmaceuticals, Inc. (DFFN)

Stock Price: $1.15 USD 0.01 (0.88%)
Updated Aug 5, 2020 9:55 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 68.14M
Revenue (ttm) n/a
Net Income (ttm) -11.61M
Shares Out 59.63M
EPS (ttm) -0.80
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 5, 2020
Last Price $1.15
Previous Close $1.14
Change ($) 0.01
Change (%) 0.88%
Day's Open 1.13
Day's Range 1.13 - 1.18
Day's Volume 341,200
52-Week Range 0.21 - 2.42

More Stats

Market Cap 68.14M
Enterprise Value 57.53M
Earnings Date (est) Aug 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 59.63M
Float 45.86M
EPS (basic) -1.05
EPS (diluted) -0.80
FCF / Share -0.31
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 461,652
Short Ratio 0.24
Short % of Float 0.93%
Beta 2.14
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 3.96
Revenue n/a
Operating Income -11.59M
Net Income -11.61M
Free Cash Flow -10.71M
Net Cash 10.60M
Net Cash / Share 0.18
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -39.10%
ROE -75.25%
ROIC -2,335.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$3.50*
Low
3.50
Current: $1.15
High
3.50
Target: 3.50
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue-------0.370.570.04
Revenue Growth--------34.35%1319.48%-
Gross Profit-------0.14-1.74-0.17
Operating Income-11.55-18.96-11.35-18.37-6.41-14.61-9.07-11.79-16.43-4.70
Net Income-11.80-18.37-1.36-18.04-6.72-14.35-2.64-6.87-22.64-8.41
Shares Outstanding6.713.240.830.680.170.100.020.010.01-
Earnings Per Share-1.76-8.21-29.11-26.40-38.40-149.99-149.99-1,223.94-3,899.81-2,099.90
Operating Cash Flow-9.86-10.77-12.33-10.77-5.19-9.03-1.18-4.31-12.02-1.98
Capital Expenditures---0.45--0.04-0.05---0.12-0.01
Free Cash Flow-9.86-10.77-12.78-10.77-5.23-9.08-1.18-4.31-12.15-1.99
Cash & Equivalents14.187.998.901.552.0021.880.250.310.100.04
Total Debt0.25-0.552.431.24-1.874.000.562.12
Net Cash / Debt13.937.998.35-0.880.7521.88-1.61-3.69-0.46-2.08
Assets24.1118.2026.1517.482.2842.7818.342.453.675.58
Liabilities3.982.594.928.302.324.6111.8820.8519.685.56
Book Value20.1315.6121.239.18-0.0438.176.46-18.39-16.030.02
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Diffusion Pharmaceuticals, Inc.
Country United States
Employees 10
CEO David G. Kalergis

Stock Information

Ticker Symbol DFFN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: DFFN

Description

Diffusion Pharmaceuticals Inc., a clinical stage biotechnology company, develops treatments for life-threatening medical conditions. Its lead product candidate is transcrocetinate sodium, which is in Phase III trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of metastatic brain cancer; and Phase II trial for the treatment of acute stroke. The company is also developing RES-529, a PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of age-related macular degeneration; and is in pre-clinical development stage for the treatment of oncology primarily GBM. Diffusion Pharmaceuticals Inc. has a cooperative research agreement with the University of Virginia Health and the Integrated Translational Research Institute of Virginia to evaluate the transcrocetinate sodium in patients with acute respiratory distress syndrome associated with COVID-19 infection. The company was founded in 2001 and is headquartered in Charlottesville, Virginia.